Charles River Laboratories Intl. Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while abrdn Physical Palladium Shares ETF trades at $20.92 (market cap $586.03M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 24.3× abrdn Physical Palladium Shares ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| CRL | PALL | |
|---|---|---|
Market Cap | $14.23B | $586.03M |
Volume | 1,176,885 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $310.77 | $37.18 |
52-Week Low | $149.93 | $20.30 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
PALL trades at $20.77, up 2.32% today, but technical indicators show a bearish trend with moving averages unanimously negative. The ETF faces fundamental data gaps in valuation and profitability metrics. Recent news highlights palladium's underperformance versus other precious metals, with some analysts seeing current price weakness as a buying opportunity given supply risks and industrial demand potential.
The outlook remains cautious with strong bearish technical signals offset by potential catch-up trade opportunities. Key risks include commodity price volatility and industrial demand fluctuations, while potential upside depends on palladium market dynamics reversing recent weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →